GRADE Study Group

Quick facts

Phase 3 pipeline

• DPP-4 inhibitor (sitagliptin) · Diabetes
  Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.
• Sulfonylurea (glimepiride) · Diabetes
  Glimepiride works by stimulating insulin release from the pancreatic beta cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• GRADE Study Group portfolio CI brief
• GRADE Study Group pipeline updates RSS